Cronos Group And 2 Other Noteworthy Penny Stocks On The TSX

In This Article:

The Canadian market is currently navigating a complex landscape of trade developments, central bank meetings, and fiscal debates, all contributing to potential volatility. Despite these challenges, the fundamentals remain supportive of growth, providing a backdrop where investors might explore opportunities in various sectors. Though the term 'penny stocks' might feel like a relic from past market eras, they still offer potential for growth when backed by strong financials. In this article, we explore three noteworthy penny stocks on the TSX that exemplify this blend of affordability and potential upside.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

PetroTal (TSX:TAL)

CA$0.65

CA$594.7M

★★★★★☆

Orezone Gold (TSX:ORE)

CA$1.37

CA$722.21M

★★★★★☆

Dynacor Group (TSX:DNG)

CA$4.52

CA$190.97M

★★★★★★

Findev (TSXV:FDI)

CA$0.435

CA$12.46M

★★★★★★

Thor Explorations (TSXV:THX)

CA$0.69

CA$459.06M

★★★★★★

Automotive Finco (TSXV:AFCC.H)

CA$0.75

CA$14.86M

★★★★★★

NTG Clarity Networks (TSXV:NCI)

CA$2.39

CA$101.54M

★★★★★★

Intermap Technologies (TSX:IMP)

CA$2.47

CA$141.24M

★★★★★☆

Pulse Seismic (TSX:PSD)

CA$2.82

CA$143.13M

★★★★★★

Hemisphere Energy (TSXV:HME)

CA$1.79

CA$173.06M

★★★★★★

Click here to see the full list of 874 stocks from our TSX Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Cronos Group

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cronos Group Inc. is a cannabinoid company involved in the cultivation, production, distribution, and marketing of cannabis products across Canada, Israel, and internationally with a market cap of CA$1.05 billion.

Operations: The company's revenue is primarily derived from the cultivation, manufacture, and marketing of cannabis and cannabis-derived products, totaling $124.59 million.

Market Cap: CA$1.05B

Cronos Group Inc., with a market cap of CA$1.05 billion, has shown significant financial developments, becoming profitable in the past year with net income reaching US$6.12 million for Q1 2025 compared to a loss previously. The company has initiated a share repurchase program worth $50 million, indicating confidence in its valuation and future prospects. Despite low return on equity at 4.5%, Cronos is debt-free and maintains strong liquidity with short-term assets significantly exceeding liabilities. Recent product innovations and strategic leadership changes aim to bolster its market position amidst anticipated revenue growth of 9.74% annually.